Every letter we have printed

The testing market for this subject is thin because the demand is thin, and the demand is thin because the certificate does not have a field for it. Formats create markets. Add a sterility line to the standard template and somebody will start selling the test within a year.

Research-grade material is not sold as sterile, is not claimed to be sterile and is not approved for human use in any jurisdiction. That is a straightforward statement of what the grade is, and your department is one of the few places in this trade where it is made without embarrassment.

Tapering is borrowed language from drug classes with withdrawal syndromes, and there is no equivalent phenomenon here. Whether a gradual reduction changes the trajectory is an open question rather than an established practice, and the borrowed word implies an answer.

Tapering is described in the community literature with a confidence the published evidence does not support. There is no trial that compares a taper against an abrupt stop in this class, and the absence should be stated wherever the practice is discussed.

Ion suppression is the point I would put in bold. A species that ionises poorly in the presence of an excess of something that ionises well can be present at several per cent and invisible in the spectrum. Absence of a peak is not absence of a compound, and the report cannot tell you which you have.

Charge-state distribution is diagnostic and almost always discarded. A peptide that normally presents as a triply and quadruply charged pair, appearing this time as a broad ladder, is telling you something about its conformation or its buffer. The information is in the file and never in the summary.

One request for the standing checklist. Ask whether the spectrum was acquired on the same sample preparation as the chromatography or on a separate weighing. If separate, the two sections of the certificate describe two different aliquots, and a reader is entitled to know that before drawing the two together.

The plateau discussion in community settings has a strong survivorship character. People whose trajectory continued do not post about a plateau, so the visible discussion overstates how universal the experience is.

Weight trajectories in the published trials flatten well before the study ends, and the curve shape is one of the most useful things a reader can be shown. Expectations set on the early gradient are set on a section of a curve that does not continue.

Thank you for saying plainly that the maximum dose is not the goal. I stopped at 10 mg fourteen months ago because it was working and I was tired of arguing about it. Every article I read before yours implied I had given up early.

I would like to see the phrase "area normalisation" appear on certificates that use it. It is not a defect; it is a method with a stated assumption, which is that everything present absorbs equally at the detection wavelength. The assumption is false for peptides and the arithmetic proceeds regardless.

The threshold discussion needs one more sentence. A reporting threshold and an integration threshold are different settings, and software will let you set them independently. A method can integrate down to 0.01 per cent and report nothing below 0.10 per cent, and the resulting certificate is honest, complete and impossible to compare with anything.

Your worked example uses valley-to-valley integration throughout. Tangential skim on a shoulder eluting off the main peak will hand a slice of the impurity back to the product and move the figure in the flattering direction. It is a legitimate choice with a published rationale, and it is invisible on the certificate.

The article assumes the baseline is a decision made once. On a shallow gradient with an absorbing mobile-phase additive it drifts through the run, and where the software anchors that drift moves small late peaks in and out of existence. Two analysts, same file, different answer, neither of them wrong.

I run a small teaching laboratory and I use this department as reading for second-year students. The point that lands hardest with them is that four defensible analytical choices can move a reported figure by nearly two points without anyone behaving badly. They arrive believing measurement is a fact and leave understanding it is a procedure.

Your submission design has a hole in it. Eight vials from one lot cannot separate variation between laboratories from variation between vials, because you have no replicate within a laboratory to estimate the second. Two vials each is a start and it is not enough, and the honest conclusion from your table is that the four figures differ, not that the laboratories do.

Loss of confidence in the material is a reason your taxonomy does not include and I have seen repeatedly. A batch that behaved differently from the previous one ends more arrangements than any pharmacological consideration, and it is a supply-quality question rather than a clinical one.

Nobody separates the reason for the first stop from the reason for the last one. People who stop and restart several times have a pattern, and a pattern is more informative than any single event within it.

Nobody discusses what maintenance does to the appetite for other interventions. Several accounts I have read describe a period in which nothing else was attempted because the current arrangement was working, and the cost of that pause only becomes visible later.

Duration of follow-up drives incidence mechanically: a longer study finds more of everything. Comparing rates between studies of different lengths without annualising is a category error and it is done constantly.

Trial populations were selected, monitored and supported in ways that the general population is not, and event reporting in a trial is systematic in a way that reporting outside one never is. Both facts push the comparison in opposite directions and neither is usually mentioned.

The vagal afferent pathway is the part of the story with the strongest experimental support and the weakest presence in general discussion, presumably because it is harder to draw. Mechanistic coverage tends to follow what can be diagrammed.

The relationship between escalation rate and reported effects is one of the better-supported findings in the area and it is stated as folklore rather than as evidence in most discussion. The underlying data is real and it is worth citing properly.

The interesting number is not how many people experienced an effect but how many changed what they were doing because of it. The second is collected in most trials and reported in few.

A small point of precision. You use "gastroparesis" in the tag list and then spend a paragraph saying it is not a synonym for drug-induced emptying delay. That is a slightly awkward position to hold.

Reporting on management would be improved by a single distinction: approaches with randomised evidence, approaches with observational evidence, and approaches with none. Most articles mix all three in one list.

I teach a seminar that uses two of your pieces as set reading. Students arrive expecting advocacy and are visibly unsettled by the refusal to supply any.

A practical point about drawing up. A needle wide enough to withdraw viscous solution quickly is not the needle anybody wants for the injection itself, and swapping between them is normal practice rather than fussiness. The dead volume in the hub is also a real loss on small quantities.

Gauge and length are chosen in this market largely by anecdote, while the published work on the subject in adjacent clinical contexts is extensive and specific. The evidence exists and is not being read.

I gave myself a tenth of my intended dose for five weeks. I had been using insulin syringes, ran out, and used the 1 mL syringes that came with the vials, which are marked in millilitres. I did not notice because the plunger was in roughly the same place. Nobody warned me these were different scales.

The comparison your readers want is between an excursion and the stability data that would justify tolerating it. Without accelerated stability figures for the specific formulation, an excursion assessment is judgement dressed as calculation. Very few suppliers in this trade hold those figures.

A logger recording every five minutes and a logger recording hourly will produce different excursion findings on the same journey, because the short spike at the depot falls between readings. Sampling interval is a specification and it is almost never quoted with the logger data.

Monoisotopic and average mass differ by enough at peptide scale to matter, and the two are quoted interchangeably in supplier literature. For a forty-residue sequence the gap is a couple of daltons, which is exactly the size of the modification a buyer might be trying to exclude.

A small point on units. Parts per million mass accuracy is a proportion, so five parts per million on a small peptide is a few thousandths of a dalton and on a large one is rather more. Quoting an accuracy specification without the mass it applies to is the same error your chromatography pieces complain about.

Timing matters as much as reason. Stopping in week three and stopping in year three are different events with different consequences, and reporting a single discontinuation rate for a study collapses that entirely.

Supply interruption is a reason people stop that has nothing to do with anybody’s decision, and it produces the same physiological sequence as a planned stop with none of the preparation. The supply reporting elsewhere in the issue is directly relevant here.

Reporting the median rather than the mean would change the appearance of most of these results, because the distributions are skewed. Where both are available the gap between them is itself informative and it is almost never printed.

A properly blind purchase means buying as an ordinary customer, from the ordinary catalogue, with no indication that the vial is going anywhere but a domestic address. Anything less and the supplier has had an opportunity, however small, to treat that order differently.

Sample size defeats most of what is published. A single blind purchase from one supplier tells you about one vial. It is worth having and it is not a characterisation of anything, and the gap between those two statements is where most confusion in this market lives.

The submitter-pays problem is real and I think you overstate it slightly. A laboratory that shades results towards its customers loses the only asset it has the moment a second laboratory disagrees in public. The incentive to please the payer is immediate; the incentive to be right is larger and slower.